| Literature DB >> 31355778 |
Kunihiko Araki1, Amane Araki1, Daiyu Honda1, Takako Izumoto2, Atsushi Hashizume1, Yasuhiro Hijikata1, Shinichiro Yamada1, Yohei Iguchi1, Akitoshi Hara3, Kazuhiro Ikumi1, Kaori Kawai1, Shinsuke Ishigaki1, Yoko Nakamichi4, Shin Tsunekawa2, Yusuke Seino5, Akiko Yamamoto6, Yasunori Takayama7, Shihomi Hidaka5, Makoto Tominaga7, Mica Ohara-Imaizumi4, Atsushi Suzuki5, Hiroshi Ishiguro6, Atsushi Enomoto3, Mari Yoshida8, Hiroshi Arima2, Shin-Ichi Muramatsu9,10, Gen Sobue11, Masahisa Katsuno1.
Abstract
TAR DNA-binding protein 43 kDa (TDP-43), encoded by TARDBP, is an RNA-binding protein, the nuclear depletion of which is the histopathological hallmark of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder affecting both upper and lower motor neurons. Besides motor symptoms, patients with ALS often develop nonneuronal signs including glucose intolerance, but the underlying pathomechanism is still controversial, i.e., whether it is impaired insulin secretion and/or insulin resistance. Here, we showed that ALS subjects reduced early-phase insulin secretion and that the nuclear localization of TDP-43 was lost in the islets of autopsied ALS pancreas. Loss of TDP-43 inhibited exocytosis by downregulating CaV1.2 calcium channels, thereby reducing early-phase insulin secretion in a cultured β cell line (MIN6) and β cell-specific Tardbp knockout mice. Overexpression of CaV1.2 restored early-phase insulin secretion in Tardbp knocked-down MIN6 cells. Our findings suggest that TDP-43 regulates cellular exocytosis mediated by L-type voltage-dependent calcium channels and thus plays an important role in the early phase of insulin secretion by pancreatic islets. Thus, nuclear loss of TDP-43 is implicated in not only the selective loss of motor neurons but also in glucose intolerance due to impaired insulin secretion at an early stage of ALS.Entities:
Keywords: ALS; Calcium channels; Insulin; Metabolism; Neuroscience
Year: 2019 PMID: 31355778 PMCID: PMC6715357 DOI: 10.1172/JCI124481
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808